Finding new ways to improve cancer immunotherapy
Discovery of Novel Therapeutic Strategies for Cancer Immunotherapy
This study is looking into why important immune cells called T-cells have trouble getting into tumors to fight cancer, and it hopes to find out more about a specific protein that might be blocking their way, which could help develop better treatments for cancer patients.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Yale University NIH-funded |
| Lab location | 1 site (New Haven, United States) |
| Project ID | NIH-10988986 on NIH RePORTER |
What this research studies
This research investigates why T-cells, which are crucial for fighting cancer, often fail to infiltrate tumors. The team hypothesizes that certain proteins produced by tumors, known as T-cell excluders, prevent T-cells from entering and functioning effectively. By using advanced screening techniques, they aim to identify and understand these proteins, particularly focusing on a candidate called SLIT2, which has been shown to inhibit T-cell movement towards tumor signals. This could lead to new therapeutic strategies that enhance T-cell responses in cancer patients.
Who could benefit from this research
Good fit: Ideal candidates for this research are cancer patients with tumors that exhibit low T-cell infiltration.
Not a fit: Patients with tumors that do not have issues with T-cell infiltration may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to improved cancer treatments by enhancing the ability of T-cells to attack tumors.
How similar studies have performed: Other research has shown promise in targeting T-cell migration in cancer therapy, suggesting that this approach could be a meaningful advancement.
Where this research is happening
New Haven, United States
- Yale University — New Haven, United States (Active)
Researchers
- Principal investigator: Yang, Xuan — Yale University
- Study coordinator: Yang, Xuan
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.